U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    46,786.42
    +176.92 (+0.38%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Lannett: Fiscal 2Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA (AP) _ Lannett Co. (LCI) on Wednesday reported a fiscal second-quarter loss of $171.9 million, after reporting a profit in the same period a year earlier.

On a per-share basis, the Philadelphia-based company said it had a loss of $4.36. Earnings, adjusted for one-time gains and costs, came to 8 cents per share.

The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was also for earnings of 8 cents per share.

The generic drug company posted revenue of $133.9 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $130.1 million.

Lannett expects full-year revenue in the range of $480 million to $500 million.

Lannett shares have climbed 15% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $7.48, a decline of 12% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LCI at https://www.zacks.com/ap/LCI